Page 236 - Read Online

Page 8 of 10 Reiss et al. Vessel Plus 2020;4:19 I http://dx.doi.org/10.20517/2574-1209.2020.04

23. Reiss AB, Wan DW, Anwar K, Merrill JT, Wirkowski PA, et al. Enhanced CD36 scavenger receptor expression in THP-1 human
monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis. Exp Biol Med (Maywood) 2009;234:354-60.
24. Reiss AB, Awadallah N, Malhotra S, Montesinos MC, Chan ESL, et al. Immune complexes and interferon-γ decrease cholesterol
27-hydroxylase in human arterial endothelium and macrophages. J Lipid Res 2001;42:1913-22.
25. Reiss AB, Patel CA, Rahman MM, Chan ES, Hasneen K, et al. IFN-gamma impedes reverse cholesterol transport and promotes foam cell
transformation in THP-1 human monocytes/macrophages. Med Sci Monit 2004;10:BR420-5.
26. Reiss AB. Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus. Curr Rheumatol Rep
2009;11:255-60.
27. Voloshyna I, Modayil S, Littlefield MJ, Belilos E, Belostocki KB, et al. Plasma from rheumatoid arthritis patients promotes pro-
atherogenic cholesterol transport gene expression in THP-1 human macrophages. Exp Biol Med (Maywood) 2013;238:1192-7.
28. Tan L, Liu L, Jiang Z, Hao X. Inhibition of microRNA-17-5p reduces the inflammation and lipid accumulation, and up-regulates ATP-
binding cassette transporterA1 in atherosclerosis. J Pharmacol Sci 2019;139:280-8.
29. Choromańska B, Myśliwiec P, Choromańska K, Dadan J, Chabowski A. The role of CD36 receptor in the pathogenesis of atherosclerosis.
Adv Clin Exp Med 2017;26:717-22.
30. Reardon CA, Lingaraju A, Schoenfelt KQ, Zhou G, Cui C, et al. Obesity and insulin resistance promote atherosclerosis through an IFNγ-
regulated macrophage protein network. Cell Rep 2018;23:3021-30.
31. Zhu Y, Xian X, Wang Z, Bi Y, Chen Q, et al. Research progress on the relationship between atherosclerosis and inflammation.
Biomolecules 2018;8:80.
32. Zhang L, Peppel K, Sivashanmugam P, Orman ES, Brian L, et al. Expression of tumor necrosis factor receptor-1 in arterial wall cells
promotes atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:1087-94.
33. Howe KL, Fish JE. Transforming endothelial cells in atherosclerosis. Nat Metab 2019;1:856-7.
34. Yu XH, Zhang J, Zheng XL, Yang YH, Tang CK. Interferon-γ in foam cell formation and progression of atherosclerosis. Clin Chim Acta
2015;441:33-43.
35. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-7.
36. Hu D, Hannah J, Gray RS, Jablonski KA, Henderson JA, et al. Effects of obesity and body fat distribution on lipids and lipoproteins in
nondiabetic american indians: the strong heart study. Obes Res 2000;8:411-21.
37. Franssen R, Monajemi H, Stroes ES, Kastelein JJ. Obesity and dyslipidemia. Med Clin North Am 2011;95:893-902.
38. Jellinger PS, Mehta AE, Smith DA, Handelsman Y, Ganda, O, et al.; AACE Task Force for Management of Dyslipidemia and Prevention
of Atherosclerosis. American Association of Clinical Endocrinologists’ Guidelines for management of dyslipidemia and prevention of
atherosclerosis. Endocr Pract 2012;18:1-78.
39. Rashid S, Genest J. Effect of obesity on high-density lipoprotein metabolism. Obesity 2007;15:2875-88.
40. Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013;5:1218-40.
41. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-600.
42. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, et al. The Residual Risk Reduction Initiative: a call to action to reduce
residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102:1K-34K.
43. Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J
2005;81:358-66.
44. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus:
the case for residual risk reduction after statin treatment. Open Cardiovasc Med J 2011;5:24-34.
45. Ottaviani E, Malagoli D, Franceschi C. The evolution of the adipose tissue: a neglected enigma. Gen Comp Endocrinol 2011;174:1-4.
46. Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012;126:1301-13.
47. Van Dam AD, Boon MR, Berbee JFP, Rensen PCN, Van Harmelen V. Targeting white, brown and perivascular adipose tissue in
atherosclerosis development. Eur J Pharmacol 2017;816:82-92.
48. Frühbeck G, Gómez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling
in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001;280:E827-47.
49. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97.
50. Liberale L, Bonaventura A, Vecchiè A, Casula M, Dallegri F, et al. The role of adipocytokines in coronary atherosclerosis. Curr
Atheroscler Rep 2017;19:10.
51. Blüher, M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 2009;117:241-50.
52. Ohman MK, Shen Y, Obimba CI, Wright AP, Warnock M, et al. Visceral adipose tissue inflammation accelerates atherosclerosis in
apolipoprotein E-deficient mice. Circulation 2008;117:798-805.
53. Pollack RM, Donath MY, LeRoith D, Leibowitz G. Anti-inflammatory agents in the treatment of diabetes and its vascular complications.
Diabetes Care 2016;39:S244-52.
54. O’Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, et al. Effect of darapladib on major coronary events after an acute
coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 2014;312:1006-15.
55. Reiss AB, Vernice NA, Siegart NM, De Leon J, Kasselman LJ. Exosomes in cholesterol metabolism and atherosclerosis. Cardiovasc
Hematol Disord Drug Targets 2017;17:185-94.
56. Hoeke G, Kooijman S, Boon MR, Rensen PCN, Berbée JF. Role of Brown fat in lipoprotein metabolism and atherosclerosis. Circ Res
2016;118:173-82.
57. Xiong W, Zhao X, Villacorta L, Rom O, Garciabarrio MT, et al. Brown adipocyte-specific PPARγ (peroxisome proliferator-activated